- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease progression and sometimes carry risks of severe side effects, such as liver failure or viral infections, says GlobalData. According to research by the leading data and […]
NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM). As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven mostly by international pharmaceutical companies, but lacks substantial […]
Promising Phase I data sets latecomer Amgen’s AMG-133 on a trajectory to compete with Novo Nordisk and Eli Lilly in obesity space, says GlobalData
Amgen’s AMG-133* has the potential to address a key unmet need for drugs that reduce patient burden among patients with obesity, says GlobalData, a leading data and analytics company. Sara Reci, Pharma Analyst at GlobalData, comments: “Currently, patients receiving pharmacotherapy for obesity, such as glucagon-like peptide-1 receptor (GLP-1R), are required to self administer Wegovy (semaglutide) […]
Congenital fibrinogen deficiency market will surpass $800 million across the 3MM by 2031, driven by demand for plasma-derived therapies, says GlobalData
The congenital fibrinogen deficiency (CFD) market is forecast to increase from $673 million in 2021 to over $800 million in 2031 at a compound annual growth rate (CAGR) of 1.7% across the three major markets (3MM*). Growth will be driven by the launch of improved human fibrinogen concentrate (HFC) products, the large market potential for HFC […]
Bispecific antibodies will threaten cell therapy in multiple myeloma in 2023, says GlobalData
A relatively novel class of drugs called bispecific T-cell engagers (BiTEs) present a serious threat to the market position of Bristol Myers-Squibb’s Abecma (ide-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) as they leverage clinical advantages such as improved duration of response to therapy and quicker administration, says GlobalData, a leading data […]
Pulmonary arterial hypertension market expected to reach $7.5 billion in 2029 across 7MM, forecasts GlobalData
The pulmonary arterial hypertension (PAH) market in the seven major markets (7MM*) is expected to increase from $4.6 billion in 2019 to $7.5 billion in 2029 at a compound annual growth rate (CAGR) of 5%, driven by the launch of pipeline therapies and an increased uptake in combination therapy, according to GlobalData, a leading data […]
Global autism spectrum disorder market to reach $4.0 billion by 2031 driven by novel pipeline agents, says GlobalData
The autism spectrum disorder (ASD) market is expected to grow from $985.5 million in 2021 to $4.0 billion by 2031 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 15.1%, according to GlobalData, a leading data and analytics company. ASD is a highly heterogenous disorder with a wide range of […]
Brexit could be a major setback for Alzheimer’s disease drug development, says GlobalData
Despite the growing demand for novel therapeutics to treat Alzheimer’s disease, just one innovator drug has been approved in the last decade by the UK’s Medicines and Healthcare Products Regulatory Agency (MRHA), according to GlobalData’s Drugs Database. The leading data and analytics company notes that the high costs of research combined with the post-Brexit regulatory […]
Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide symptomatic relief. However, as these therapies do not target the pathophysiological mechanisms underlying the pain, they typically only work in a subset of patients, and provide only partial pain relief. Furthermore, the established marketed analgesics have been associated with poor safety profiles. […]
Historically unimpressive field of therapeutic cancer vaccines gets revitalized with Moderna and Merck mRNA data, says GlobalData
Historically, therapeutic cancer vaccines have demonstrated minimal efficacy. However, for the first time, an anti-cancer vaccine has shown significant promise in a clinical trial. The combination therapy of Moderna’s mRNA vaccine “mRNA-4157/V940” in combination with Merck & Co’s anti-PD-1 therapy “Keytruda” has reportedly cut the risk of melanoma recurrence or death by 44% compared to […]
Strong uptake expected for AbbVie’s Vraylar in major depressive disorder market, says GlobalData
Following the news that AbbVie’s Vraylar (cariprazine) gained approval from the FDA for the adjunctive treatment of major depressive disorder (MDD) in adults; Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “In the MDD market, there is a need for therapies that can treat patients who are inadequately responding […]
Small molecule approvals for rare diseases in China reaches all-time highs in 2022, says GlobalData
Small molecule approvals for rare diseases in China recorded a staggering 300% growth from just 3 to 12 between 2019 and 2022 due to swift regulations set by the National Medical Products Administration (NMPA). As a result, the trend of increasing approvals had now reached all time-highs in 2022, says GlobalData, a leading data and […]
Three pipeline multiple sclerosis drugs bring hope to primary progressive patients, according to GlobalData
Three of the 20 drugs currently being developed for primary progressive multiple sclerosis (PPMS) are now in Phase III of development, according to leading data and analytics company GlobalData, offering hope to the patients, who have very few treatment options in comparison to patients affected by relapsing remitting multiple sclerosis (RRMS). MS is an autoimmune […]
China aims to lead next bio revolution with investments in advanced biologics, says GlobalData
China initiated a 10-year “Made in China 2025” plan in 2015 as part of a strategy to reduce dependence on foreign technology and emerge as a global leader in several high-tech industries, including biotech. Since then, the country has significantly invested in improving its cell and gene therapy manufacturing capabilities as it attempts to lead […]
Dupixent’s safety concerns unlikely to impact prescriptions, says GlobalData
Recently, the UK’s Medicines, and Healthcare Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Sanofi & Regeneron’s Dupixent, a drug used in the treatment of numerous allergic indications. Leading data and analytics company, GlobalData, notes that, although this safety update will likely raise physician vigilance regarding long-term Dupixent […]
CanSino Biologics inhaled vaccine Convidecia Air to gain good momentum amid plans to boost elderly vaccination in China, says GlobalData
In a clear shift away from its long-held stringent zero-COVID policy, China has recently relaxed rules that contained the spread of the virus but impacted the world’s second largest economy. Subsequently, the National Health Commission (NHC) pledged to step up vaccination among the elderly. Against this backdrop, considering that CanSino Biologics’ inhaled vaccine Convidecia Air […]
50% of healthcare industry professionals would prioritize investing in AI in the next two years, finds GlobalData survey
According to a survey by GlobalData, 50% of healthcare industry professionals would prioritize artificial intelligence (AI) among other emerging technologies for their investments in the next two years. The leading data and analytics company notes that AI has been trending as the leading future investment target in the pharmaceutical industry since 2018, gaining a 6% […]
GOSH TvT CAR7 Phase I: Positive trial results with CRISPR base-edited CAR-T cells is a significant step in treating cancer, says GlobalData
Following the news that the first patient in the UCL Great Ormond Street Insititute of Child Health’s (GOSH) Phase I TvT CAR7 trial to treat pediatric relapsed/refractory T-cell acute lymphoblastic leukemia, has gone into remission; James Donagher, Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “While the GOSH […]
Potential prophylactic antibiotic use for Strep A infections highlights need for vaccine, says GlobalData
Following the news that, amid rising cases and deaths nationally, antibiotics could be administered prophylactically in UK schools with cases of streptococcus A (Strep A); Fiona Chisholm, Associate Director at GlobalData, a leading data and analytics company, offers her view: “Health officials are under increased pressure to curb inappropriate use of antibiotics and rarely give […]
High demand leaves Ozempic compensating for Wegovy’s supply shortage, says GlobalData
Novo Nordisk announced on 4 November 2022, that they had a witnessed a growth in the sales of Ozempic (semaglutide), which is indicated for type 2 diabetes (T2D). The increase may be attributed to supply shortages of Wegovy (semaglutide), indicated for obesity, due to its high demand and manufacturer production problems. Ozempic is currently compensating […]